, Volume 226, Issue 3, pp 475–490 | Cite as

Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles

  • G. A. Higgins
  • L. B. Silenieks
  • W. Lau
  • I. A. M. de Lannoy
  • D. K. H. Lee
  • J. Izhakova
  • K. Coen
  • A. D. Le
  • P. J. Fletcher
Original Investigation



Selective 5-HT2C receptor agonists, such as lorcaserin, are being developed for the treatment of obesity. Studies suggest that they may also have therapeutic potential for addictive behaviours including nicotine dependence, although few drugs of this class have been evaluated.


The primary aim was to evaluate the highly selective 5-HT2C agonist, CP-809101, against food-motivated (operant FR5 and progressive ratio schedules, palatability-induced feeding) and nicotine-motivated (intravenous self-administration, drug discrimination) behaviours in rats and to compare with equivalent findings for the structurally distinct 5-HT2C receptor agonists lorcaserin and Ro 60–0175. The secondary aims were to evaluate the side effect profiles of lorcaserin and CP-809101 and to determine the plasma levels of lorcaserin at a dose (1 mg/kg) that reduces both food and nicotine reinforcement for comparison to plasma concentrations reported in human trials.


CP-809101 (0.3–3 mg/kg SC) reduced responding for both nicotine and food and blocked the discriminative stimulus properties of nicotine in a similar manner to lorcaserin and Ro 60–0175. Behaviours such as hypolocomotion, chewing and ptosis became evident following both CP-809101 and lorcaserin administration at higher doses. Plasma levels of lorcaserin were of similar range to those reported in obesity trials.


These studies support the utility of 5-HT2C agonists as a therapeutic approach to treat nicotine dependence. Plasma exposure levels after acute lorcaserin treatment suggest that equivalent dosages could be used to evaluate these drugs in obesity and smoking cessation trials. Finally, there may be differences in the side effect profiles between lorcaserin and CP-809101, raising the possibility for tolerability differences amongst 5-HT2C agonists.


Functional selectivity Nicotine self-administration Nausea 5-HT2C agonist Lorcaserin CP-809101 Ro 60–0175 Pharmacokinetics Rat 



We wish to acknowledge the statistical support of Sandy Thevarkunnel (InterVivo Solutions Inc). Bioanalytical method development and sample analysis were performed under the guidance of Dr. Henrianna Pang (NoAb BioDiscoveries Inc.).

Conflict of interest

The authors have no conflict of interest to declare.


  1. Arena Pharmaceuticals (2010) Briefing document: NDA 22–529; lorcaserin hydrochloride (APD356)Google Scholar
  2. Benaliouad F, Zhornitsky S, Rompré PP (2011) Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2C receptors. Behav Brain Res 217:467–471PubMedCrossRefGoogle Scholar
  3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94–104PubMedGoogle Scholar
  4. Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP (2008) A conservative, single-amino acid substitution in the second cytoplasmic domain of the human serotonin 2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharm Exp Ther 324:1084–1092CrossRefGoogle Scholar
  5. Bubar MJ, Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971–1985PubMedCrossRefGoogle Scholar
  6. Burns CM, Chu H, Reuter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387:303–308PubMedCrossRefGoogle Scholar
  7. Corrigall WA, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited access schedule. Psychopharmacology 99:473–478PubMedCrossRefGoogle Scholar
  8. Cousins MS, Wei W, Salamone JD (1994) Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative and stimulant drugs. Psychopharmacology 116:529–537PubMedCrossRefGoogle Scholar
  9. Dekeyne A, Girardon S, Millan MJ (1999) Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60–0175: a pharmacological analysis. Neuropharmacology 38:415–423PubMedCrossRefGoogle Scholar
  10. Desai RI, Barber DJ, Terry P (2003) Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology 167:335–343PubMedGoogle Scholar
  11. Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin2C/2B receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53–61PubMedCrossRefGoogle Scholar
  12. Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E (2006) Central serotonin2C receptor: from physiology to pathology. Curr Top Med Chem 6:1909–1925PubMedCrossRefGoogle Scholar
  13. du Sert N, Holmes AM, Willis R, Andrews PLR (2012) Predicting the emetic liability of novel chemical entities: a comparative study. Br J Pharmacol 165:1848–1867CrossRefGoogle Scholar
  14. Filip M, Spampinato U, McCreary AC, Przegalinski E (2012) Pharmacological and genetic interventions in serotonin (5-HT)2C receptors to alter drug abuse and dependence processes. Brain Res 1476:132–153PubMedCrossRefGoogle Scholar
  15. Fletcher PJ, Le AD, Higgins GA (2009a) Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res 172:361–383CrossRefGoogle Scholar
  16. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA (2009b) Characterising the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice. Neuropharmacology 57:259–267PubMedCrossRefGoogle Scholar
  17. Fletcher PJ, Rizos Z, Noble K, Soko A, Silenieks LB, Le AD, Higgins GA (2012) Effects of the 5-HT2C receptor agonist Ro 60–0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology 62:2287–2297CrossRefGoogle Scholar
  18. Garfield AS, Heisler LK (2009) Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 587:49–60PubMedCrossRefGoogle Scholar
  19. Grottick AJ, Corrigall WA, Higgins GA (2001) Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology 157:292–298PubMedCrossRefGoogle Scholar
  20. Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007) Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67:27–55PubMedCrossRefGoogle Scholar
  21. Henningfield JE, Shiffman S, Ferguson SG, Gritz ER (2009) Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 123:1–16PubMedCrossRefGoogle Scholar
  22. Higgins GA, Fletcher PJ (2003) Serotonin and reward: focus on 5-HT2C receptors. Eur J Pharmacol 480:151–162PubMedCrossRefGoogle Scholar
  23. Higgins GA, Joharchi N, Sellers EM (1993) Behavioral effects of the 5-hydroxytryptamine3 receptor agonists 1-phenylbiguanide and m-chlorophenylbiguanide in rats. J Pharm Exp Ther 264:1440–1449Google Scholar
  24. Higgins GA, Ouagazzal A, Grottick AJ (2001) Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro 60–0175 and the indirect 5-HT agonist dexfenfluramine. Br J Pharmacol 133:459–466PubMedCrossRefGoogle Scholar
  25. Higgins GA, Silenieks LB, Roβmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ (2012) The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology 37:1177–1191PubMedCrossRefGoogle Scholar
  26. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR (2009) Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 157:857–880CrossRefGoogle Scholar
  27. Hurren KM, Berlie HD (2011) Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Sys Pharm 68:2029–2037CrossRefGoogle Scholar
  28. Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, Woods JH (2011) Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharm Exp Ther 339:194–202CrossRefGoogle Scholar
  29. Kacew S, Festing MF (1996) Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. J Toxicol Environ Health 47:1–30PubMedGoogle Scholar
  30. Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV, Soliman VF, Schildknegt K (2007) Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2C receptor agonist for the treatment of obesity: role of metabolic activation. Drug Metab Dispos 35:848–858PubMedCrossRefGoogle Scholar
  31. Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. TIPS 16:232–238PubMedGoogle Scholar
  32. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenall KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB242,084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36:609–620PubMedCrossRefGoogle Scholar
  33. Le Sage M, Shelley D, Ross JT, Carroll FI, Corrigall WA (2009) Effects of the nicotinic partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 91:461–467CrossRefGoogle Scholar
  34. Ljungberg T (1987) Blockade by neuroleptics of water intake and operant responding for water in the rat: anhedonia, motor deficit, or both? Pharmacol Biochem Behav 27:341–350PubMedCrossRefGoogle Scholar
  35. Millan MJ, Dekeyne A, Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953–955PubMedCrossRefGoogle Scholar
  36. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S (2011) Suicidal behavior and depression in smoking cessation treatments. PLoS One 11:e27016CrossRefGoogle Scholar
  37. Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharm Exp Ther 321:1054–1061CrossRefGoogle Scholar
  38. Nilsson BM (2006) 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential anti-obesity agents. J Med Chem 49:4023–4034PubMedCrossRefGoogle Scholar
  39. O’Connor EC, Parker D, Rollema H, Mead AN (2010) The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology 208:365–376PubMedCrossRefGoogle Scholar
  40. Parker LA, MacLeod KB (1991) Chin Rub CRs may reflect conditioned sickness elicited by a lithium-paired sucrose solution. Pharmacol Biochem Behav 40:983–986PubMedCrossRefGoogle Scholar
  41. Paterson N, Min W, Hackett A, Lowe D, Hanania T, Calderone B, Ghavami A (2010) The high-affinity nAchR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuro-Psychopharm Biol Psychiatry 34:1455–1464CrossRefGoogle Scholar
  42. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128:13–20PubMedCrossRefGoogle Scholar
  43. Quarta D, Naylor CG, Stolerman IP (2007) The serotonin2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology 193:391–402PubMedCrossRefGoogle Scholar
  44. Rock EM, Benzaquen J, Limbeer CL, Parker LA (2009) Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phoshodiesterase-4 (PDE4) inhibitor. Pharmacol Biochem Behav 91:537–541PubMedCrossRefGoogle Scholar
  45. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD III, Williams KE (2007a) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985–994PubMedCrossRefGoogle Scholar
  46. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007b) Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316–325PubMedCrossRefGoogle Scholar
  47. Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K (1991) Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology 104:515–521PubMedCrossRefGoogle Scholar
  48. Shram MJ, Schoedel KA, Barlett C, Shazer RL, Anderson CM, Sellers EM (2011) Evaluation of the abuse potential evaluation of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther 89:683–692PubMedCrossRefGoogle Scholar
  49. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279–290PubMedCrossRefGoogle Scholar
  50. Smith JW, Stolerman IP (2009) Recognising nicotine: the neurobiological basis of nicotine discrimination. Handb Exp Pharmacol 192:295–333PubMedCrossRefGoogle Scholar
  51. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M (2007) Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalize to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157–170PubMedCrossRefGoogle Scholar
  52. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR (2006) Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 1:1194–1206PubMedCrossRefGoogle Scholar
  53. Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG (2007) 5-HT2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur J Neurosci 25:3115–3124PubMedCrossRefGoogle Scholar
  54. Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308–315PubMedCrossRefGoogle Scholar
  55. Stafford SA, Tang K, Coote JH (2006) Activation of lumbosacral 5-HT2C receptors induces bursts of rhythmic activity in sympathetic nerves to the vas deferens in male rats. Br J Pharmacol 148:1083–1090PubMedCrossRefGoogle Scholar
  56. Stout BD, Clarke WP, Berg KA (2002) Rapid desensitization of the serotonin2C receptor system: effector pathways and agonist dependence. J Pharm Exp Ther 302:957–962CrossRefGoogle Scholar
  57. Strong PV, Greenwood BN, Fleshner M (2009) The effects of the selective 5-HT(2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats. Psychopharmacology 203:665–675PubMedCrossRefGoogle Scholar
  58. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espita S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577–587PubMedCrossRefGoogle Scholar
  59. Urban JD, Clarke WP, Zastrow MV, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharm Exp Ther 320:1–13CrossRefGoogle Scholar
  60. Vickers SP, Clifton PG, Dourish CT (1996) Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Psychopharmacology 125:168–175PubMedCrossRefGoogle Scholar
  61. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA (2001) Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists. Pharmacol Biochem Behav 69:643–652PubMedCrossRefGoogle Scholar
  62. Wacker DA, Miller KJ (2008) Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr Opin Drug Discov Devel 11:438–445PubMedGoogle Scholar
  63. Werry TD, Loiacono R, Sexton PM, Christopoulos A (2008) RNA editing of the serotonin 5-HT2C receptor and its effects on cell signaling, pharmacology and brain function. Pharmacology Ther 119:7–23CrossRefGoogle Scholar
  64. Zaniewska M, McCreary AC, Przegalinski E, Filip M (2007) Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 571:156–165PubMedCrossRefGoogle Scholar
  65. Zaniewska M, McCreary AC, Stefański R, Przegaliński E, Filip M (2008) Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats. Synapse 62:935–939PubMedCrossRefGoogle Scholar
  66. Zaniewska M, McCreary AC, Filip M (2009) Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. Synapse 63:653–661PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • G. A. Higgins
    • 1
    • 2
  • L. B. Silenieks
    • 1
  • W. Lau
    • 1
  • I. A. M. de Lannoy
    • 3
  • D. K. H. Lee
    • 3
  • J. Izhakova
    • 3
  • K. Coen
    • 4
  • A. D. Le
    • 4
    • 2
  • P. J. Fletcher
    • 4
    • 5
    • 6
  1. 1.InterVivo Solutions IncTorontoCanada
  2. 2.Department of PharmacologyUniversity of TorontoTorontoCanada
  3. 3.NoAb BiodiscoveriesMississaugaCanada
  4. 4.Centre for Addiction and Mental HealthTorontoCanada
  5. 5.Department of PsychologyUniversity of TorontoTorontoCanada
  6. 6.Department of PsychiatryUniversity of TorontoTorontoCanada

Personalised recommendations